Coherus Refiles US On-Body Pegfilgrastim, With Potential For 2023 Approval
Coherus BioSciences has swiftly returned a filing for its on-body pegfilgrastim biosimilar candidate to the US Food and Drug Administration, while hitting a milestone for its Cimerli biosimilar to Lucentis (ranibizumab)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.